Cystic fibrosis

Sales Tips and Mindset Shifts: Klyn Elsbury Relaunches Website with a Brand Refresh and Upcoming Virtual Workshop

Retrieved on: 
Tuesday, December 5, 2023
Learning, Success (magazine), City, Woman, Cystic fibrosis, Diabetes, NBC Nightly News, Hospital, Keynote, Terminal, Patient, Organization, News, Life, Sales

Featured in hundreds of media programs and periodicals, including Forbes, NBC Nightly News with Lester Holt, and Success Magazine.

Key Points: 
  • Featured in hundreds of media programs and periodicals, including Forbes, NBC Nightly News with Lester Holt, and Success Magazine.
  • The Total Reset equips sales, high-performance, and leadership teams with tools to improve focus, productivity, and resilience.
  • Companies will spend time getting to know each other on a more intimate level and learning how to optimize the performance of their sales teams.
  • Visit Kyln’s website , klynelsbury.com, to learn more about her upcoming Virtual Workshop on Friday, December 15th, which is designed to help recruit salespeople and the 72 tour dates she’s already booked for 2024.

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Retrieved on: 
Thursday, November 30, 2023
Urinary tract infection, University of California, Disease, Cystic fibrosis, Mortality, Pseudomonas aeruginosa, University, Phage therapy, Infection, Part, BOLT, Patient, NESS, KOL, Pharmaceutical industry

(University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.

Key Points: 
  • (University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.
  • Jonathan Solomon, Chief Executive Officer of BiomX, will review topline results from Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, as a potential treatment for chronic pulmonary infections caused by P. aeruginosa in CF patients.
  • BiomX is developing BX004, utilizing its proprietary BOLT platform, to address a significant unmet need facing thousands of CF patients who require new treatments to combat persistent and deadly lung infections.
  • P. aeruginosa is a main contributor to morbidity and mortality in patients with CF.

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Retrieved on: 
Wednesday, November 29, 2023
Patient, Colistin, Culture, Infection, Division, Șaeș, Tobramycin, Aztreonam, Lung, Cystic fibrosis, FEV1, Pediatrics, Therapy, Pseudomonas aeruginosa, University, Phage therapy, Part, Safety, NESS, KOL, Pharmaceutical industry

“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX.

Key Points: 
  • “These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX.
  • Patients were on the same inhaled antibiotic (tobramycin, aztreonam, or colistin) from Day 1-10 (treatment period) and through Day 28 of the study.
  • BX004 vs. placebo showed a positive clinical effect in a predefined subgroup of patients with reduced baseline lung function (FEV1
  • BiomX management will host a conference call and webcast today at 9:00 am ET to review the results of Part 2 of the Phase 1b/2a trial results.

Calgary’s Oldest Women-Only Charity Golf Classic Ends after 34 Years

Retrieved on: 
Tuesday, November 28, 2023
Survival, Infection, Human, Research, Cystic fibrosis, Cystic Fibrosis Canada, Disease, Death, Organization

CALGARY, Alberta, Nov. 28, 2023 (GLOBE NEWSWIRE) -- On September 21, 2023 the 34th and final 65 Roses Ladies Golf Classic was held at The Winston Golf Club. This tournament was the longest running women-only tournament in Calgary and has raised over 1.25 million dollars in support of Cystic Fibrosis Canada. The final year of this tournament we raised $27,000 for cystic fibrosis.

Key Points: 
  • CALGARY, Alberta, Nov. 28, 2023 (GLOBE NEWSWIRE) -- On September 21, 2023 the 34th and final 65 Roses Ladies Golf Classic was held at The Winston Golf Club.
  • This tournament was the longest running women-only tournament in Calgary and has raised over 1.25 million dollars in support of Cystic Fibrosis Canada.
  • While we did not meet our final goal it was a wonderful day of celebration for all our accomplishments.
  • The Winston did an incredible job of hosting us and course was in beautiful shape.

Claire’s Place Foundation Welcomes Mara Fortin to Board of Directors

Retrieved on: 
Tuesday, November 28, 2023
Growth, Cystic fibrosis, Light, CFO, Video game

Los Angeles, CA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Claire’s Place Foundation , a non-profit organization providing support to children and families affected by cystic fibrosis (CF), welcomes Mara Fortin, successful small business founder and franchise owner, to the organization’s board of directors.

Key Points: 
  • Los Angeles, CA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Claire’s Place Foundation , a non-profit organization providing support to children and families affected by cystic fibrosis (CF), welcomes Mara Fortin, successful small business founder and franchise owner, to the organization’s board of directors.
  • As a former attorney and the sole owner responsible for every part of her small businesses, Mara has worn multiple hats.
  • Following, Mara founded a thriving consultancy, KKN Consulting, LLC, where she assists clients to achieve sustainable growth.
  • “Every so often, someone comes into our lives and touches our soul on a deep and profound level,” said Mara Fortin.

Molecular Cytogenetics Market Size, Share & Trends Analysis Report 2023-2030 - A $4.46 billion by 2030, with CAGR of 10.6% from 2023 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 28, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Infectious Diseases, Hospitals, Genetics, Clinical Trials, AIR, NGS, Down syndrome, WHO, Cystic fibrosis, Incidence, Thermo Fisher Scientific, DSM-IV codes, Personalized medicine, USD, Knowledge, COVID-19, Public, Cytogenetics, Genomics, CGH, Growth, FISH

The global molecular cytogenetics market size is anticipated to reach USD 4.46 billion by 2030.

Key Points: 
  • The global molecular cytogenetics market size is anticipated to reach USD 4.46 billion by 2030.
  • The market is expected to expand at a CAGR of 10.6% from 2023 to 2030.
  • Thus, the high incidence of diagnostic testing during the pandemic has fueled the growth of the market for molecular cytogenetics.
  • Moreover, rising strategic initiatives by operating players for technological advancements in cytogenetic tools are projected to propel the market for molecular cytogenetics.

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Drug development, Disease, NESS, Safety, NYSE, Policy, Senior, Food, Cystic fibrosis, Plasma protein binding, H.262/MPEG-2 Part 2, Workforce, Sputum, Clinical trial, Mortality, Insurance, Patient, Research, Part, FDA, Pharmacokinetics, Bacteria, Novartis, Conference, Pseudomonas aeruginosa, FEV1, Communication, CFU, Dermatology, Physician, Psoriatic arthritis, Fast Track, Part Two, Pharmaceutical industry, Medical imaging, Cryptocurrency

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.

Key Points: 
  • and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.
  • In addition, the U.S. Food and Drug Administration recently granted Fast Track designation for BX004, further underscoring the potential of this promising program.
  • Net loss for the third quarter of 2023 was $7.9 million, compared to $6.8 million for the same period in 2022.
  • Net cash used in operating activities for the nine months ended September 30, 2023, was $15.0 million, compared to $21.9 million for the same period in 2022.

ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines

Retrieved on: 
Monday, November 13, 2023
CNS, BGF, Brain, Cystic fibrosis, Head, IBEC, Science, Tissue, Biological engineering, Patient, Small RNA, Asos, Pancreas, Messenger, UCL, Eli Lilly, Therapy, Plasmid, Nanomedicine, Central nervous system, Cystic Fibrosis Foundation, ICREA, Vaccine, Pharmaceutical industry

Formerly known as SomaServe, ViaNautis has secured support from a consortium of prominent global investors enabling the advancement of its proprietary drug delivery platform – polyNaut®.

Key Points: 
  • Formerly known as SomaServe, ViaNautis has secured support from a consortium of prominent global investors enabling the advancement of its proprietary drug delivery platform – polyNaut®.
  • ViaNautis’s polyNaut® platform applies advanced polymer materials and in silico screening to precisely guide genetic molecules such as pDNA, mRNA, siRNA and ASOs to their intended targets.
  • ViaNautis presents an excellent opportunity in the world of genetic therapies by enabling the delivery of cargoes to otherwise inaccessible sites of action in the body.
  • It opens a plethora of novel prospects in the world of genetic therapies, offering the ability to reach previously inaccessible treatment sites.

4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Thursday, November 9, 2023
PRISM, Ophthalmology, D, European Medicines Agency, Cystic fibrosis, Cystic Fibrosis Foundation, Atypical hemolytic uremic syndrome, Security (finance), Risk, Clinical trial, Patient, Research, DME, Completeness, FDA, Cash, VG, AMD, ASRS, CFTR, AAV, Pharmaceutical industry

“The third quarter of 2023 was another period of tremendous progress across our large market product candidate portfolio,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

Key Points: 
  • “The third quarter of 2023 was another period of tremendous progress across our large market product candidate portfolio,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • R&D Expenses: Research and development expenses were $25.1 million for the quarter ended September 30, 2023 as compared to $18.9 million for the third quarter of 2022.
  • G&A Expenses: General and administrative expenses were $9.1 million for the quarter ended September 30, 2023 as compared to $8.1 million for the third quarter of 2022.
  • Net Loss: Net loss was $10.3 million for the quarter ended September 30, 2023, as compared to net loss of $25.7 million for the third quarter of 2022.

Genetic Testing's Role in Personalized Medicine and Targeted Therapies for Respiratory Conditions - ResearchAndMarkets.com

Retrieved on: 
Monday, December 18, 2023
Health, Genetics, Personalized medicine, COPD, Genome-wide association study, Disorder, Prevalence, Granulomatous–lymphocytic interstitial lung disease, Privacy, Risk, Diagnosis, GWAS, Respiratory disease, Marker beacon, Region, Genetic testing, Health information management, Growth, Chronic obstructive pulmonary disease, Asthma, Cystic fibrosis, Agriculture, Pharmaceutical industry, Vaccine, Medical device

Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions.

Key Points: 
  • Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions.
  • Factors contributing to this growth include the rising prevalence of respiratory diseases, advances in genetic testing technologies, and increasing awareness of personalized medicine.
  • Personalized Medicine: Genetic testing allows healthcare providers to tailor treatment plans to an individual's genetic profile, enhancing treatment efficacy and minimizing adverse effects.
  • Targeted Therapies: Genetic testing results are guiding the development of targeted therapies for specific respiratory diseases, leading to more effective and precise treatment options.